PDSB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PDSB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, PDS Biotechnology's PE Ratio without NRI is 0.00. PDS Biotechnology's 5-Year EBITDA growth rate is 35.50%. Therefore, PDS Biotechnology's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for PDS Biotechnology's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for PDS Biotechnology's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDS Biotechnology Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
PDS Biotechnology Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, PDS Biotechnology's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PDS Biotechnology's PEG Ratio distribution charts can be found below:
* The bar in red indicates where PDS Biotechnology's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
PDS Biotechnology's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 35.50 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
PDS Biotechnology (NAS:PDSB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of PDS Biotechnology's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Spencer D. Brown | officer: Senior VP, General Counsel | 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932 |
Matthew C Hill | officer: Chief Financial Officer | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044 |
Delyle W Bloomquist | director, 10 percent owner | RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207 |
Voorhees Seth Van | officer: Chief Financial Officer | 12 HARVEY DRIVE, SHORT HILLS NJ 07078 |
Kamil Ali-jackson | director | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Gregory Gene Freitag | director | 13631 PROGRESS BLVD., ALACHUA FL 32615 |
Stephen C. Glover | director | 108 DOCKSIDE CIRCLE, WESTON FL 33327 |
Otis W Brawley | director | 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518 |
Michael N. King | officer: Interim Chief Financial Office | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Ilian Iliev | director | 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Janetta Trochimiuk | officer: Principal Accounting Officer | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Richard Sykes | director | C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932 |
Frank Bedu-addo | director, 10 percent owner, officer: President/CEO | 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922 |
Lauren Wood | officer: Chief Medical Officer | 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922 |
Gregory Conn | officer: Chief Scientific Officer | 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922 |
From GuruFocus
By Marketwired • 05-09-2024
By Marketwired • 11-06-2024
By Marketwired • 05-15-2024
By GuruFocus Research • 03-27-2024
By Marketwired • 09-09-2024
By Marketwired • 07-31-2024
By Marketwired • 05-03-2024
By Marketwired • 05-07-2024
By GuruFocus News • 11-15-2024
By Marketwired • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.